Financial and Legal Burdens and Discrimination after Surviving a Childhood Cancer Diagnosis in Germany—Results from a Survey in the German Childhood Cancer Survivor Community
Journal of Adolescent and Young Adult Oncology · 2026
DOI: 10.1089/jayao.2025.0026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Adolescent and Young Adult Oncology, 2026. Verfasst von Bjoern Hessing und 6 weiteren Autor:innen. Beteiligte Einrichtung: Survivor Deutschland e.V., Deutsche Kinderkrebsstiftung der Deutschen Leukämie-Forschungshilfe, Bonn, Germany. Hauptthemen laut MEDLINE: Neoplasms, Cancer Survivors, Survivors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Since survival rates have improved over recent decades, there is an increasing number of childhood cancer survivors. Besides the late medical effects of the therapy, survivors experience financial and legal burdens and discrimination linked to their cancer history. The objective of this study was to examine the prevalence and types of discrimination faced by childhood cancer survivors in Germany.
Methods
We conducted a survey in the German childhood cancer community assessing domains of discrimination.
Results
Within 111 participants, recruited through social media campaigns and direct outreach to organizations in the field of pediatric oncology, 76.6% ( n = 85) reported experiencing at least one form of discrimination. The most common areas of discrimination involved various types of insurance coverage (51.4%), employment (27.9%), and educational matters (16.2%).
Conclusion
Our findings highlight the significant prevalence of lifelong financial and legal burdens and discrimination among childhood cancer survivors. It reveals the urgent need for education, awareness campaigns regarding cancer survival, and legal measures to end discrimination and to establish equal treatment in terms of social and financial issues. Our results contribute to the ongoing discussion surrounding the law named “Right to be Forgotten” and advocate an implementation in Germany.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Survivor Deutschland e.V., Deutsche Kinderkrebsstiftung der Deutschen Leukämie-Forschungshilfe, Bonn, Germany.
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Diagnostic and Interventional Radiology, Clinic for Radiology and Nuclear Medicine, Hospital of the Goethe University Frankfurt, Frankfurt am Main, Germany.
- Parental Analytic PDS&T, AbbVie Deutschland GmbH & Co. KG, Knollstraße, Ludwigshafen, Germany.
- Department of Paediatrics and Adolescent Medicine, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
ORCID-Profile: Eva-Maria Wild
Zitieren
APA
Hessing, B., Luedersen, J., Scharping, L., Zehbe, A., Gotta, J., Alfes, M., & Wild, E. M. (2026). Financial and Legal Burdens and Discrimination after Surviving a Childhood Cancer Diagnosis in Germany—Results from a Survey in the German Childhood Cancer Survivor Community. Journal of Adolescent and Young Adult Oncology. https://doi.org/10.1089/jayao.2025.0026
Vancouver
Hessing B, Luedersen J, Scharping L, Zehbe A, Gotta J, Alfes M, et al. Financial and Legal Burdens and Discrimination after Surviving a Childhood Cancer Diagnosis in Germany—Results from a Survey in the German Childhood Cancer Survivor Community. Journal of Adolescent and Young Adult Oncology. 2026. doi:10.1089/jayao.2025.0026
BibTeX
@article{Hessing2026,
author = {Hessing, Bjoern and Luedersen, Jette and Scharping, Lisa and Zehbe, Astrid and Gotta, Jennifer and Alfes, Marie and Wild, Eva-Maria},
title = {Financial and Legal Burdens and Discrimination after Surviving a Childhood Cancer Diagnosis in Germany—Results from a Survey in the German Childhood Cancer Survivor Community},
journal = {Journal of Adolescent and Young Adult Oncology},
year = {2026},
doi = {10.1089/jayao.2025.0026}
}
EUVIMED